MX2013006362A - Terapia de combinacion. - Google Patents

Terapia de combinacion.

Info

Publication number
MX2013006362A
MX2013006362A MX2013006362A MX2013006362A MX2013006362A MX 2013006362 A MX2013006362 A MX 2013006362A MX 2013006362 A MX2013006362 A MX 2013006362A MX 2013006362 A MX2013006362 A MX 2013006362A MX 2013006362 A MX2013006362 A MX 2013006362A
Authority
MX
Mexico
Prior art keywords
interferon
cancer
combination therapy
vemurafenib
treatment
Prior art date
Application number
MX2013006362A
Other languages
English (en)
Inventor
Kapil Dhingra
Brian Higgins
Kenneth Kolinsky
Kathryn E Packman
Richard J Lee
Brian Lestini
Fei Su
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013006362A publication Critical patent/MX2013006362A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a una terapia de combinación con la {3-[5-(4-clorofenil)-1H-pirrolo[2,3-b]-piridina-3-carbonil]-2,4 -difluor-fenil}-amida del ácido pro-pano-1-sulfónico o una sal farmacéuticamente aceptable de la misma y un interferón para tratar un paciente que sufra un trastorno proliferativo, en especial un tumor sólido, por ejemplo, el cáncer colorrectal, el melanoma y el cáncer de tiroides. La presente invención se refiere en especial a dicha terapia, en la que el interferón es el peginterferón alfa-2a y el trastorno es un melanoma que contenga la b-Raf con la mutación V600E.
MX2013006362A 2010-12-14 2011-12-12 Terapia de combinacion. MX2013006362A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42269010P 2010-12-14 2010-12-14
PCT/EP2011/072408 WO2012080151A1 (en) 2010-12-14 2011-12-12 Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2013006362A true MX2013006362A (es) 2013-07-30

Family

ID=45370460

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006362A MX2013006362A (es) 2010-12-14 2011-12-12 Terapia de combinacion.

Country Status (13)

Country Link
US (2) US9295669B2 (es)
EP (1) EP2651414A1 (es)
JP (1) JP5757544B2 (es)
KR (2) KR101628448B1 (es)
CN (1) CN103370066B (es)
AR (1) AR084233A1 (es)
BR (1) BR112013014642A2 (es)
CA (1) CA2819426A1 (es)
HK (1) HK1185808A1 (es)
MX (1) MX2013006362A (es)
RU (1) RU2592983C2 (es)
TW (1) TWI468161B (es)
WO (1) WO2012080151A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
ES2743427T3 (es) 2012-08-17 2020-02-19 Hoffmann La Roche Politerapias para melanoma que comprenden administrar cobimetinib y vemurafinib
ES2642162T3 (es) * 2015-03-26 2017-11-15 Ratiopharm Gmbh Composición que comprende vemurafenib y HPMC-AS
WO2017004421A1 (en) * 2015-06-30 2017-01-05 The Trustees Of The University Of Pennsylvania Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions
NZ755835A (en) 2017-01-17 2023-12-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN112245570A (zh) * 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法
AU2022210179A1 (en) * 2021-01-21 2023-09-07 Biosteed Gene Transformation Tech. Co., Ltd. Interferon-based cancer treatment method, and pharmaceutical combination

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516807A (en) 1994-10-25 1996-05-14 Warner-Lambert Company Method for treating vascular proliferative disorders following balloon angioplasty
ATE330600T1 (de) 2000-01-26 2006-07-15 Schering Corp Kombinationspräparat zur krebstherapie
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
NZ522766A (en) 2000-05-15 2005-09-30 Celgene Corp Compositions and methods for the treatment of colorectal cancer with irinotecan and thalidomide to reduce side effects
RU2003113538A (ru) 2000-10-13 2004-11-10 Вайон Фармасьютикалз, Инк. (Us) Модифицированные пролекарственные формы ap/amp
RU2179859C1 (ru) 2001-05-22 2002-02-27 Центральный научно-исследовательский рентгено-радиологический институт Способ лечения почечно-клеточного рака
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20080193445A1 (en) 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US20050176740A1 (en) 2002-04-08 2005-08-11 Spector Neil L. Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
JP2006520368A (ja) 2003-03-19 2006-09-07 アレス トレーディング ソシエテ アノニム アルツハイマー病の治療
BRPI0409484A (pt) 2003-04-17 2006-05-02 Ares Trading Sa interferon beta em sìndrome respiratória aguda severa (sars)
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
CA2550361C (en) 2003-12-19 2014-04-29 Prabha Ibrahim Compounds and methods for development of ret modulators
US20070281041A1 (en) 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
CA2566971A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with irinotecan (cpt-11) and an egfr-inhibitor
KR100851271B1 (ko) 2004-06-03 2008-08-08 에프. 호프만-라 로슈 아게 이리노테칸 （ｃｐｔ-１１） 및 ｅｇｆｒ-억제제를 이용한치료
EP1785484B1 (en) 2004-06-30 2011-06-01 Japan Science and Technology Agency Oligonucleotide inhibiting tumor cell proliferation and method therefor
KR20080003422A (ko) 2005-04-14 2008-01-07 메르크 파텐트 게엠베하 종양 조직 내의 ｅｇｆｒ 유전자의 증가된 복제수에 기초한항-ｅｇｆｒ 항체 치료
EP1917019A2 (en) 2005-05-03 2008-05-07 Biopolymer Engineering, Inc. Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
US20060257400A1 (en) 2005-05-13 2006-11-16 Bristol-Myers Squibb Company Combination therapy
BRPI0611863B1 (pt) 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
EP2130822A1 (en) 2005-12-01 2009-12-09 F. Hoffmann-La Roche AG 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
JP2009535372A (ja) 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
CA2662508A1 (en) 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
TW200901975A (en) 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
JP5563455B2 (ja) 2007-08-01 2014-07-30 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の新規な合成アゴニスト
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
AU2010236606A1 (en) 2009-04-14 2011-11-03 Merck Sharp & Dohme Corp. Interferon-alfa sensitivity biomarkers
MX2011012311A (es) 2009-05-21 2011-12-14 Schering Corp Marcadores geneticos asociados con la respuesta al interferon alfa.
CA2771369A1 (en) 2009-08-24 2011-03-10 Genentech, Inc. Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
JP2013538856A (ja) 2010-10-01 2013-10-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Also Published As

Publication number Publication date
AR084233A1 (es) 2013-05-02
US20160256529A1 (en) 2016-09-08
US20120148533A1 (en) 2012-06-14
CA2819426A1 (en) 2012-06-21
TW201300107A (zh) 2013-01-01
US9295669B2 (en) 2016-03-29
EP2651414A1 (en) 2013-10-23
CN103370066A (zh) 2013-10-23
WO2012080151A1 (en) 2012-06-21
TWI468161B (zh) 2015-01-11
CN103370066B (zh) 2015-09-09
JP5757544B2 (ja) 2015-07-29
RU2592983C2 (ru) 2016-07-27
JP2013545772A (ja) 2013-12-26
KR20160031039A (ko) 2016-03-21
RU2013130926A (ru) 2015-01-20
KR101628448B1 (ko) 2016-06-08
BR112013014642A2 (pt) 2020-08-11
KR20130092617A (ko) 2013-08-20
HK1185808A1 (zh) 2014-02-28

Similar Documents

Publication Publication Date Title
MX2013006362A (es) Terapia de combinacion.
WO2012022677A3 (en) Combination therapy for the treatment of cancer
MY161288A (en) Combination anti - cancer therapy
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
MY168791A (en) Carbamate compounds and of making and using same
NZ602478A (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
MX2013010770A (es) Tratamiento de tumores solidos.
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
NZ592825A (en) A triazolothiadiazole inhibitor of c-met protein kinase
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
IL206563A (en) A preparation or drug containing a suspension of blood cells that contain asparaginase for use in the treatment of pancreatic cancer
MX349120B (es) Compuesto heterociclico aromatico que contiene nitrogeno.
NZ712184A (en) Combination therapy comprising a b-raf inhibitor and a second inhibitor
GEP20166455B (en) Methods of administering pirfenidone therapy
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
MX342001B (es) Tratamiento de artritis por lupus usando laquinimod.
MX2012007813A (es) Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional.
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
MX2013006319A (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek.
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
WO2007130501A3 (en) Combination therapy for treatment of cancer
UA106214C2 (ru) Ингибиторы митоза для интенсификации процесса апоптоза при терапии
MX357770B (es) Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer.